BPC-157 Grown in Bacteria: 82.9% Ulcer Inhibition in Rats

A group at the Tianjin University of Science and Technology published work on 29 August 2026 describing something almost every paper on this compound skips: not what it does, but how you make it.

They integrated the coding sequence into the chromosome of a bacterium, optimised the fermentation, purified the product, and only then took it to an animal model.

For anyone who supplies or buys this material, the production question is the more consequential of the two, and it is the one with almost no published literature behind it.

A framing note. This is an animal study. Peptra Labs supplies BPC-157 as a reference material for laboratory research only, and nothing below is guidance about human use or about treating anything.

What the group built

The host was Bacillus licheniformis strain 2709, a bacterium already used industrially for enzyme production. The authors report stable expression achieved by chromosomal integration rather than by plasmid, which is the more demanding route and the one that does not need antibiotic selection to hold the construct in place.

They made two constructs, and neither is the bare peptide. The first fuses BPC-157 to gamma-glutamyltranspeptidase. The second fuses it to mScarlet, a red fluorescent protein used as a reporter.

That design choice is the technical heart of the paper. BPC-157 is fifteen amino acids long. A peptide that short is difficult to express in a bacterium and harder still to recover from the broth, because the cell degrades it and standard purification steps do not hold on to something so small. Fusing it to a much larger protein gives the construct enough mass and structure to survive expression and to be captured, and the fluorescent partner additionally makes the yield visible without a separate assay.

The fermentation numbers

The authors optimised growth conditions using single-factor experiments followed by an orthogonal design, which is a structured way of testing several variables at once rather than one at a time.

The conditions they report as optimal are a 2 percent inoculum, 40 g/L soybean peptone and 80 g/L glucose. Under those conditions, reporter-based expression signal increased roughly threefold against the basal medium.

Purification was by fractional ammonium sulfate precipitation, an old and cheap separation method that drops proteins out of solution in order of how strongly they hold on to water. The authors report optimal saturations of 50 percent for one fusion protein and 60 percent for the other.

None of that is glamorous, and all of it is the part that determines whether a laboratory process can be scaled or repeated.

What the animal test showed

The material was then tested in rats with acute gastric ulcers induced by ethanol, a standard and severe model in which alcohol strips the stomach lining directly.

The authors also report that histological analysis showed reduced mucosal inflammation and stimulated glandular repair, and that the cytokine reductions were measured by ELISA in gastric tissue.

Two regimes were used, one where the material was given before the ethanol and one after. Both produced inhibition in the same range, with the therapeutic regime marginally higher, which is unusual enough to be worth noting rather than explaining, since the abstract does not give the mechanism.

The authors conclude that the results suggest a biotechnological production strategy for BPC-157 and applications for gastric ulcer treatment. The first half of that sentence is what the data support. The second half is their extrapolation from a rat model, and it should be read as such.

The limitation that matters most

What was administered to the rats was the fusion protein, not free BPC-157.

That is not a quibble. GGT-BPC157 and mScarlet-BPC157 are large molecules of which the fifteen-residue sequence is a small fraction. Their absorption, distribution and clearance will differ from those of the isolated peptide, and any activity observed could in principle come from the fusion partner, from the construct as a whole, or from peptide released by cleavage in the gut.

The abstract does not report a cleavage step that liberates the free peptide before testing, and it does not report a comparison against synthetic BPC-157 run in the same experiment. Without that arm, the paper demonstrates that the constructs work in this model. It does not establish that recombinantly produced BPC-157 matches the synthetic material laboratories currently use.

That comparison is the obvious next experiment, and its absence is the single most important thing to carry away from this paper.

How BPC-157 is made today

Essentially all BPC-157 in circulation is made by solid-phase peptide synthesis, in which the chain is assembled one residue at a time on a resin. For a fifteen-mer that is an efficient and well-characterised process, and it produces a defined product whose impurities are mostly truncated sequences.

Biological production is a different proposition. It scales differently, it introduces host-derived impurities rather than synthetic ones, and it requires the fusion strategy this paper describes.

There is one prior attempt in the literature. In 2018, a Slovenian group at the Jožef Stefan Institute, working with Sikirić in Zagreb, engineered Lactococcus lactis to display BPC-157 on its surface or secrete it into the medium, using fusions to a membrane protein or to a peptidoglycan binding domain. That work was aimed at mucosal delivery rather than at bulk production, and it ran into the same constraint: the peptide had to be attached to something bigger.

Two papers, eight years apart, both concluding that the practical route runs through a fusion. That is a consistent finding about the molecule, not a coincidence of design.

What this means for a laboratory

The distinction between a synthetic and a recombinant preparation is not academic once both exist on the market.

Two materials with the same nominal sequence, made by different routes, are different products with different impurity profiles and different documentation requirements. Identity confirmation by mass spectrometry tells you the mass is right; it does not tell you what else came along, and a host-cell protein background is a question that never arises with synthetic material.

Everything in our own catalogue is supplied on a research use only basis, and our BPC-157 research reference hub collects the published work on the compound.

Most of that published work is about effects. We covered a Harvard review of the pain literature earlier this month and a rat tendon healing study alongside TB-500, and we maintain a mechanistic comparison of the two. Against that volume, the number of papers on how the material is actually manufactured is close to two.

For a field where identity and purity are the recurring questions, that imbalance is worth naming.

References

• Zhang H, Shao L, Feng Q, Guo Q, Wang H, Zhang H. Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis. Applied Biochemistry and Biotechnology, 29 August 2026. doi 10.1007/s12010-026-05885-6
• Škrlec K, Ručman R, Jarc E, Sikirić P, et al. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Applied Microbiology and Biotechnology, December 2018, 102(23):10103-10117. doi 10.1007/s00253-018-9333-6
• Becejac T, Cesarec V, Drmić D, et al. An endogeous defensive concept, renewed cytoprotection/adaptive cytoprotection: intra(per)-oral/intragastric strong alcohol in rat. Involvement of pentadecapeptide BPC 157 and nitric oxide system. Journal of Physiology and Pharmacology, June 2018

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.